排便障碍是帕金森病中慢性便秘的常见原因之一
Shivabalan Kathavarayan Ramu1, Nicholas R Oblizajek2, Rodolfo Savica3
1Research Fellow in the Enteric Neuroscience Program, Mayo Clinic, Rochester, Minnesota, USA.
Neurogastroenterology and motility
|February 20, 2024
概括
与慢性便秘患者相比,患有帕金森病和便秘 (PD-C) 的患者表现出明显的排便障碍,包括受损的挤压压力和疏散期间负的直腔梯度,与慢性便秘患者相比.
科学领域:
- 胃肠病学 胃肠病学
- 神经学 神经学
背景情况:
- 便秘影响高达50%的帕金森病患者 (PD-C).
- 在PD-C中直肠门失调的患病率在很大程度上是未知的.
- 排便障碍对PD-C的便秘有显著的贡献.
研究的目的:
- 为了比较PD-C患者的门功能与异常慢性便秘 (CC) 患者.
- 为了确定与PD-C.相关的特定排便障碍.
- 阐明帕金森病中便秘背后的机制.
主要方法:
- 使用高分辨率直肠测量仪 (HR-ARM) 来评估直肠压力,直肠感觉和直肠气球驱逐时间 (BET).
- PD-C患者与年龄和性别匹配的CC控制患者进行了比较.
- 该研究包括97名PD-C患者和173名CC患者.
主要成果:
- 40%的PD-C患者出现了排便障碍,主要是长期的BET.
- 长期BET的PD-C患者表现出更大的门静止压力和较低的直肠压力增加.
- 多变量分析显示,PD-C与较低的门挤压增加,较长的挤压持续时间,较低的直肠压力增加以及疏散期间负的直肠门梯度有关.
结论:
- 帕金森病便秘 (PD-C) 的特点是特定的直肠功能障碍.
- 这些障碍包括压缩压力受损,压缩持续时间长,直肠压力增加减少,以及疏散期间负直肠梯度.
- 研究结果将PD-C与异常性慢性便秘区分开来,这表明有不同的病理生理机制.
更多相关视频
相关概念视频
01:24Parkinson's Disease: Treatment
268
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
268
01:15Parkinson's Disease: Overview
546
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
546
01:17Chronic Bowel Disorders: Introduction
450
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
450
01:20Gastrointestinal Motility Disorders
359
Gastrointestinal or GI motility disorders are characterized by irregular gastrointestinal tract movements, disrupting food transit from the mouth to the anus. They are caused by damage or dysfunction in gut muscles or nerves. These disorders can cause symptoms such as severe constipation, diarrhea, abdominal pain, and swallowing difficulties. Disorders can affect any segment of the GI tract and range widely in severity, from common conditions like GERD to life-threatening conditions like...
359
01:17Drugs for Treatment of Diarrhea-Predominant IBS
170
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
170
01:21Drugs for Treatment of Constipation-Predominant IBS
164
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
164